In direct compression lines producing pharma-grade thiamine hydrochloride 100 mg tablets, the API is pre-sieved through a 500 µm screen and blended with microcrystalline cellulose PH-102, dibasic calcium phosphate dihydrate, croscarmellose sodium, and colloidal silicon dioxide in a 300 L V-shell blender at 25 rpm for 15 min. The high aqueous solubility of thiamine HCl, approximately 1 g in 1 mL of water according to the Ph. Eur. monograph, makes dissolution wetting less of a constraint than blend segregation and overlubrication. A pre-lubrication blend uniformity check is performed by sampling 10 points with a sample thief; the acceptance criterion is a relative standard deviation of ≤ 5.0% for a 100 mg dose, because the API often represents only 5–15% of the core weight in B-complex tablets. Magnesium stearate is added at 0.75% w/w and blended for 3 min; lubrication exceeding 5 min creates a hydrophobic film on the highly water-soluble API particles and increases disintegration time. Compression on a 27-station rotary tablet press with D tooling uses turret speed 30–45 rpm, precompression 4–6 kN, and main compression 12–18 kN. Tablet hardness is maintained at 60–90 N; friability per USP <1216> is not more than 1.0% after 100 rotations. Disintegration per USP <701> in water at 37 ± 2 °C completes in less than 15 min. Dissolution testing follows USP <711> apparatus 2, 50 rpm, 900 mL of 0.1 N hydrochloric acid at 37 ± 0.5 °C; an immediate-release acceptance criterion of Q = 75% at 45 min is used unless a product-specific monograph states otherwise. Content uniformity per USP <905> uses 10 tablets with an acceptance value of ≤ 15.0. Packaging in PVC/PVDC/aluminium blisters with desiccant canisters is specified when open-dish stability data show moisture gain above 2.0% at 40 °C/75% RH, because thiamine HCl is hygroscopic and can cause capping or sticking at higher residual moisture.

What Limits Aqueous Granulation Drying Temperature for Thiamine HCl Granules?

Because thiamine hydrochloride is heat-labile and degrades by hydrolytic ring opening at elevated temperature, aqueous low-shear granulation is operated with product temperature constraint rather than inlet air setpoint as the primary drying control. A 5% w/v povidone K30 binder solution is sprayed into a 600 L high-shear granulator containing thiamine HCl, lactose monohydrate, maize starch, and pregelatinized starch; impeller speed is 180–220 rpm, chopper speed 1500 rpm, spray rate 1.2–1.8 kg/min, and granulation time 4–7 min. The endpoint is determined by impeller power consumption rising 15–25% from the dry-mix baseline, which corresponds to a mean granule size of 200–400 µm. Overshooting the power endpoint by more than 10% produces dense granules that slow dissolution, while undergranulation leaves fine thiamine HCl segregated in the dryer. The wet mass is discharged through a conical mill fitted with a 4 mm screen and dried in a fluid-bed dryer at inlet air 60 ± 5 °C; exhaust air is held at 38–42 °C to keep product temperature below 45 °C. Drying continues until loss-on-drying by halogen moisture analyzer is 1.5–2.5%; release moisture is confirmed by Karl Fischer titration. Dried granules are sized through a 0.8 mm sieve and blended with extragranular crospovidone 2.0% w/w, colloidal silicon dioxide 0.25% w/w, and magnesium stearate 0.5% w/w for 3 min. Sachet filling uses stick-pack machines at 35–45 cycles/min; fill weight is 1.5 g ± 3.0% for a 50 mg thiamine HCl granule dose. The laminate structure is PET 12 µm / aluminium 9 µm / PE 50 µm; seal strength is tested per ASTM F88/F88M-21 with a minimum of 20 N/15 mm. Assay after 6 months at 40 °C/75% RH according to ICH Q1A is specified as 95.0–105.0% of label claim, with total degradation products not more than 1.0%. Sulfite-containing excipients are excluded from the formulation because sulfite anion cleaves the methylene bridge of thiamine and destroys activity within hours at neutral pH.

Tamping-pin capsule fillers processing thiamine HCl 10 mg into size 3 hard gelatin capsules require API pre-blending with lactose monohydrate 200 mesh at a 1:9 ratio in a 600 L bin blender for 20 min at 12 rpm; the preblend is then geometrically diluted to a final fill weight of 180 mg. Powder bed height is maintained at 18–22 mm, tamping station force at 80–120 N, and filling speed at 60,000–80,000 capsules/h. The main segregation risk arises from particle size differences between thiamine HCl, whose commercial D50 typically varies according to mill provenance, and fine lactose; this is controlled by setting blend uniformity acceptance at RSD ≤ 3.0% before encapsulation and sampling the hopper every 15 min during filling. Capsule disintegration per USP <701> is run with disks; complete disintegration in less than 15 min in 37 ± 2 °C water is required. Dissolution for hard gelatin capsules uses USP <711> apparatus 1 at 100 rpm, 900 mL of 0.1 N HCl, 37 ± 0.5 °C, with initial sampling at 15 min and Q = 75% at 45 min. Empty capsule shells are conditioned at 45–55% RH and 21–25 °C; shell moisture below 13% causes brittleness and splitting at the cap shoulder, while moisture above 16% causes softening and delayed disintegration. Weighing is performed on an automatic checkweigher with 100% inspection; net fill weight limits are ± 5.0% for a 180 mg fill, corresponding to ± 0.5 mg thiamine HCl at the 10 mg label claim. Content uniformity per USP <905> uses 10 capsules with an acceptance value of ≤ 15.0. Packaging in HDPE bottles with induction-sealed caps and 1 g silica gel desiccant is selected when long-term stability shows moisture uptake above 2.0% at 30 °C/65% RH.

When Thiamine HCl Injection Requires Nitrogen Blanketing and pH Buffering

For aqueous parenteral formulations containing thiamine HCl at 100 mg/mL, the critical quality attributes are pH, dissolved oxygen, and light exposure. The solution is prepared in Water for Injection at 15–20 °C in a stainless steel 500 L mixing vessel equipped with a nitrogen sparge line; dissolved oxygen is reduced to ≤ 0.1 mg/L before pH adjustment because oxidative degradation of thiamine is accelerated by trace metal ions such as copper and iron. pH is adjusted to 2.8–3.4 with 1 N hydrochloric acid, since thiamine HCl is most stable under acidic conditions; above pH 5.0, the thiazole ring opens and free thiol degradation products form. Alkaline hydrolysis follows first-order kinetics and increases sharply above pH 6.0; buffering with acetate or citrate is avoided unless forced degradation data support the specific container-closure system. The solution is filtered through a 0.45 µm clarifying filter followed by a sterilizing-grade 0.22 µm PVDF membrane rated per ASTM F838-20 for bacterial retention. Aseptic filling into Type I borosilicate glass vials per USP <660> is conducted under Grade A laminar flow; headspace nitrogen flushing maintains residual oxygen below 1.0% v/v. Stoppers are chlorobutyl with ETFE or FluroTec coating; stopper sterilization by gamma irradiation at 25–40 kGy is validated. Terminal steam sterilization at 121 °C for 15 min is only used if thermal stability data demonstrate assay ≥ 95.0% and total impurities ≤ 2.0% after the cycle; otherwise filtration followed by aseptic processing remains the standard for heat-sensitive thiamine HCl parenterals. Particulate matter per USP <788> Method 1 light obscuration: for containers ≤ 100 mL, particles ≥ 10 µm not more than 6000 per container and particles ≥ 25 µm not more than 600 per container. Bacterial endotoxins per USP <85> are not more than 0.50 EU/mg of thiamine HCl. Sterility per USP <71> is tested by membrane filtration. Leachables assessment follows USP <1664> for plastic components. The label specifies protection from light, storage at 15–30 °C, and incompatibility with sulfite-containing diluents, because sulfite anion destroys thiamine activity rapidly at neutral pH.

Lyophilized Thiamine HCl Cake Structure and Reconstitution Time

Freeze-drying of thiamine HCl monotherapy at 50 mg/mL fills a 5 mL solution into 10 mL Type I glass vials to a fill depth of 8–10 mm; bulking agents include mannitol or lactose at 5.0% w/v to maintain cake integrity. The freezing segment ramps shelf temperature from 20 °C to −40 °C at 0.5 °C/min and holds for 3 h to ensure complete solidification; primary drying at −20 °C shelf temperature and 150–200 mTorr for 24 h is followed by secondary drying at 25 °C for 6 h. Residual moisture by Karl Fischer is not more than 2.0% w/w for the cake, because higher residual moisture shortens reconstituted solution shelf life and accelerates thiamine degradation. The lyophilization cycle is qualified by thermocouple mapping; vial-to-vial temperature variation during primary drying should not exceed ± 2.0 °C across shelf locations. Cake appearance is inspected for collapse, meltback, and edge shrinkage; collapse indicates product temperature exceeded the collapse temperature of the formulation, which must be established by freeze-drying microscopy because published data for this specific thiamine HCl-mannitol configuration are limited. Reconstitution with 5 mL Water for Injection yields a clear solution; reconstitution time is not more than 30 seconds with gentle swirling. Reconstituted solution pH is 2.8–3.4 and is used immediately because thiamine degrades in aqueous solution under oxygen and light. Container closure integrity is verified by dye ingress per USP <1207> Type 2 and headspace oxygen analysis. Long-term storage at 2–8 °C in amber glass vials is specified when 25 °C stability data are not available.

Oral liquid vehicles containing thiamine HCl at 1.0 mg/mL are compounded at pH 3.5–4.5 to balance palatability and chemical stability; the thiamine molecule degrades rapidly above pH 6.0, and citric acid/sodium citrate buffers are used to maintain the acidic range. A typical vehicle contains sorbitol 70% w/w, glycerin, ethanol 5.0% v/v, sodium benzoate 0.1% w/v, and potassium sorbate 0.1% w/v in purified water; preservative efficacy is tested per USP <51> with bacterial and fungal challenge organisms. Manufacturing uses a 1000 L jacketed mixing vessel at 15–25 °C; the API is dissolved first in water at 20 ± 2 °C under low-light conditions, then sorbitol and glycerin are added with a high-shear mixer at 500–800 rpm for 15 min. The solution is filtered through a 5 µm polypropylene cartridge and filled into amber PET bottles with child-resistant closures; headspace oxygen is reduced by nitrogen flushing to ≤ 2.0% v/v. Light protection is critical because thiamine HCl is photolabile in dilute aqueous solution; amber PET containers comply with USP <671> spectral transmission limits. EDTA at 0.005% w/v is included as a chelator to reduce metal-catalyzed oxidation. Assay after 12 months at 25 °C/60% RH is specified as 95.0–105.0% of label claim; total degradation products are not more than 2.0%. The formula excludes sulfite salts, and the batch record specifies that stainless steel transfer lines passivated with nitric acid are used to avoid iron contamination during compounding.